These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35989498)

  • 41. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
    Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease.
    Wei W; Kong N; Liu MZ; Han T; Xu JF; Liu C
    Biochem Biophys Res Commun; 2022 Aug; 616():8-13. PubMed ID: 35636257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
    Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
    J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
    Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
    J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M
    Sultan A; Ali R; Ishrat R; Ali S
    J Biomol Struct Dyn; 2022; 40(23):12848-12862. PubMed ID: 34569411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
    Dampalla CS; Zheng J; Perera KD; Wong LR; Meyerholz DK; Nguyen HN; Kashipathy MM; Battaile KP; Lovell S; Kim Y; Perlman S; Groutas WC; Chang KO
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34210738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
    Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
    Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
    J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
    Capasso C; Nocentini A; Supuran CT
    Expert Opin Ther Pat; 2021 Apr; 31(4):309-324. PubMed ID: 33246378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
    Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2.
    Chen Y; Yang WH; Chen HF; Huang LM; Gao JY; Lin CW; Wang YC; Yang CS; Liu YL; Hou MH; Tsai CL; Chou YZ; Huang BY; Hung CF; Hung YL; Wang WJ; Su WC; Kumar V; Wu YC; Chao SW; Chang CS; Chen JS; Chiang YP; Cho DY; Jeng LB; Tsai CH; Hung MC
    J Biol Chem; 2022 Mar; 298(3):101658. PubMed ID: 35101449
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
    Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A
    Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
    Chen CC; Yu X; Kuo CJ; Min J; Chen S; Ma L; Liu K; Guo RT
    FEBS J; 2021 Sep; 288(17):5089-5121. PubMed ID: 33400393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.